100 related articles for article (PubMed ID: 31519597)
1. Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.
Kari EJM; Kuusisto MEL; Böhm J; Haapasaari KM; Teppo HR; Karihtala P; Hakalahti A; Turpeenniemi-Hujanen T; Kuittinen O
Anticancer Res; 2019 Sep; 39(9):4925-4931. PubMed ID: 31519597
[TBL] [Abstract][Full Text] [Related]
2. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
3. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Morrison VA; Weller EA; Habermann TM; Li S; Fisher RI; Cheson BD; Peterson BA
Leuk Lymphoma; 2017 Aug; 58(8):1814-1822. PubMed ID: 27967294
[TBL] [Abstract][Full Text] [Related]
4. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
5. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.
Kuusisto ME; Haapasaari KM; Turpeenniemi-Hujanen T; Jantunen E; Soini Y; Peroja P; Bloigu R; Karihtala P; Kuittinen O
J Clin Pathol; 2015 Jul; 68(7):552-6. PubMed ID: 25935550
[TBL] [Abstract][Full Text] [Related]
6. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.
Lakshmaiah KC; Asati V; Babu K G; D L; Jacob LA; M C SB; K N L; L K R; A H R; Saldanha S; Koppaka D; Patidar R; C S P
Eur J Haematol; 2018 Jun; 100(6):644-648. PubMed ID: 29569279
[TBL] [Abstract][Full Text] [Related]
7. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Jung YH; Woo IS; Han CW
Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
10. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Riihijärvi S; Nurmi H; Holte H; Björkholm M; Fluge O; Pedersen LM; Rydström K; Jerkeman M; Eriksson M; Leppä S
Eur J Haematol; 2012 Nov; 89(5):395-402. PubMed ID: 22882209
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H
Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
Kari E; Teppo HR; Haapasaari KM; Kuusisto MEL; Lemma A; Karihtala P; Pirinen R; Soini Y; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
J Clin Pathol; 2019 Apr; 72(4):316-321. PubMed ID: 30755497
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
Wu CY; Hsiao LT; Chiou TJ; Gau JP; Liu JH; Yu YB; Wu YT; Liu CJ; Huang YC; Hung MH; Chen PM; Huang YH; Tzeng CH
Leuk Lymphoma; 2015; 56(8):2357-64. PubMed ID: 25459444
[TBL] [Abstract][Full Text] [Related]
14. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
15. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma.
Abadi U; Peled L; Gurion R; Rotman-Pikielny P; Raanani P; Ellis MH; Rozovski U
Leuk Lymphoma; 2019 Dec; 60(12):2922-2926. PubMed ID: 31167584
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of platelet count in diffuse large B-cell lymphoma.
Chen LP; Lin SJ; Yu MS
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):32-7. PubMed ID: 22138101
[TBL] [Abstract][Full Text] [Related]
18. MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
Gascón P; Krendyukov A; Höbel N; Aapro M
Eur J Haematol; 2018 Mar; 100(3):241-246. PubMed ID: 29171913
[TBL] [Abstract][Full Text] [Related]
19. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
20. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
